Manish Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-06-2024
- Paid Up Capital ₹ 0.10 M
as on 20-06-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 2.50 Cr
as on 20-06-2024
- Revenue %
(FY 2018)
- Profit -289.79%
(FY 2018)
- Ebitda -49.69%
(FY 2018)
- Net Worth -1.17%
(FY 2018)
- Total Assets -54.36%
(FY 2018)
About Manish Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹2.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Manish Shah, Uttamchand Jain, and Nilesh Shah serve as directors at the Company.
- CIN/LLPIN
U51909MH2011PTC214484
- Company No.
214484
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 2011
- Date of AGM
31 Oct 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Manish Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Shah  | Director | 08-Mar-2011 | Current |
| Uttamchand Jain | Director | 08-Mar-2011 | Current |
| Nilesh Shah | Director | 08-Mar-2011 | Current |
Financial Performance of Manish Pharma.
Manish Pharma Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 289.79% decrease in profit. The company's net worth dipped by a decrease of 1.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manish Pharma?
In 2018, Manish Pharma had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Maxveda Health Private LimitedActive 4 years 1 month
Manish Shah and Uttamchand Jain are mutual person
- Medirise Life Sciences Private LimitedActive 5 years 2 months
Manish Shah, Uttamchand Jain and 1 more are mutual person
- Maxfin Holdings Private LimitedActive 3 years 5 months
Manish Shah, Uttamchand Jain and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
New India Co-Op Bank Ltd. Creation Date: 11 Oct 2011 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Manish Pharma?
Unlock and access historical data on people associated with Manish Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manish Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manish Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
